Therapeutics: Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258); epidermal growth factor receptor (EGFR); programmed cell death 1 ligan

Mouse studies suggest a TNFSF14-anti-EGFR antibody fusion protein could help treat tumors resistant to anti-PD-L1 therapies. In mice with EGFR-expressing human epidermoid carcinoma or mouse fibrosarco...